AbbVie (ABBV) Stock Forecast & Price Target

AbbVie has demonstrated strong financial performance, highlighted by an increase in global sales guidance for their Neuroscience segment to approximately $10.7 billion for 2025, alongside an uplift in overall revenue guidance for FY 2025 to around $59.7 billion. The company has also revised its non-GAAP EPS guidance upward to a range of $12.09 to $12.29, reflecting a growing outlook among key products such as Skyrizi and Rinvoq within their immunology and oncology portfolios. Furthermore, AbbVie's recent quarterly results exceeded both expectations and consensus, driven by robust sales across their core franchises, indicating a solid trajectory for future growth.

AbbVie faces several significant challenges contributing to a negative outlook, including increased competition and market erosion for its flagship product Humira as biosimilars gain market share, which may exceed initial forecasts. Additionally, the company is grappling with disappointing market penetration for key immunology products like Rinvoq and Skyrizi, alongside competitive pressures within its hematology and oncology portfolio, particularly affecting Imbruvica. Macroeconomic factors, including headwinds impacting the Aesthetics business and pipeline delays, further complicate AbbVie's growth trajectory and can adversely affect its projected revenues and earnings.